| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma (NCT07470840) | Fujian Cancer Hospital | 2027-02-01 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer (NCT07766772) | Fujian Cancer Hospital | 2026-09-30 |
| A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With Biomarkers (NCT07613905) | Fujian Cancer Hospital | 2026-09-01 |
| A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer (NCT07613567) | Fujian Cancer Hospital | 2026-09-01 |
| Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer (NCT07469306) | Fujian Cancer Hospital | 2026-08-10 |
| Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer (NCT07691333) | Fujian Cancer Hospital | 2026-06-30 |
| Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer (NCT07702708) | Fujian Cancer Hospital | 2026-06-01 |
| Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC (NCT07738367) | Fujian Cancer Hospital | 2026-04-09 |
| Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma (NCT07388836) | Fujian Cancer Hospital | 2026-03-01 |
| Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream (NCT07492654) | Fujian Cancer Hospital | 2026-03-01 |
| CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy (NCT07399158) | Fujian Cancer Hospital | 2026-02-01 |
| SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (NCT07256236) | Fujian Cancer Hospital | 2026-01-28 |
| Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study (NCT07581834) | Fujian Cancer Hospital | 2026-01-21 |
| Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) (NCT07320105) | Fujian Cancer Hospital | 2026-01-15 |
| Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II (NCT07310771) | Fujian Cancer Hospital | 2026-01-10 |
| Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma (NCT07268690) | Fujian Cancer Hospital | 2026-01-01 |
| MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC (NCT07331428) | Fujian Cancer Hospital | 2026-01-01 |
| The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver Cancer (NCT07306481) | Fujian Cancer Hospital | 2025-12-20 |
| Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance (NCT07313202) | Fujian Cancer Hospital | 2025-12-10 |
| SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases (NCT06787183) | Fujian Cancer Hospital | 2025-12-01 |
| A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma (NCT07252375) | Fujian Cancer Hospital | 2025-11-30 |
| Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment (NCT07467330) | Fujian Cancer Hospital | 2025-11-15 |
| Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal (NCT07155122) | Fujian Cancer Hospital | 2025-09-01 |
| A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy (NCT07069270) | Fujian Cancer Hospital | 2025-09-01 |
| Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery (NCT07046221) | Fujian Cancer Hospital | 2025-08-01 |
| Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma (NCT07088484) | Fujian Cancer Hospital | 2025-08-01 |
| Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC (NCT07070713) | Fujian Cancer Hospital | 2025-07-30 |
| Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma (NCT06793917) | Fujian Cancer Hospital | 2025-06-07 |
| SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma (NCT06979986) | Fujian Cancer Hospital | 2025-06-01 |
| Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer (NCT06775756) | Fujian Cancer Hospital | 2025-04-01 |
| PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM (NCT06788171) | Fujian Cancer Hospital | 2025-03-01 |
| A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer (NCT06614621) | Fujian Cancer Hospital | 2025-02-01 |
| A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer. (NCT06746545) | Fujian Cancer Hospital | 2025-02-01 |
| A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer (NCT06786312) | Fujian Cancer Hospital | 2025-01-25 |
| Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial (NCT07142122) | Fujian Cancer Hospital | 2025-01-01 |
| CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma (NCT06095154) | Fujian Cancer Hospital | 2025-01-01 |
| SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma (NCT06538935) | Fujian Cancer Hospital | 2025-01-01 |
| A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer. (NCT06654947) | Fujian Cancer Hospital | 2025-01-01 |
| Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma (NCT06572293) | Fujian Cancer Hospital | 2024-11-01 |
| Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes (NCT06490913) | Fujian Cancer Hospital | 2024-11-01 |
| Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI (NCT06441045) | Fujian Cancer Hospital | 2024-10-01 |
| Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer (NCT06600841) | Fujian Cancer Hospital | 2024-10-01 |
| Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer (NCT05628610) | Fujian Cancer Hospital | 2024-09-30 |
| Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer (NCT06140589) | Fujian Cancer Hospital | 2024-09-07 |
| Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer (NCT06333769) | Fujian Cancer Hospital | 2024-07-12 |
| Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma (NCT06468644) | Fujian Cancer Hospital | 2024-06-17 |
| Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (NCT06468670) | Fujian Cancer Hospital | 2024-06-17 |
| Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury (NCT06325982) | Fujian Cancer Hospital | 2024-06-11 |
| A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases (NCT06218888) | Fujian Cancer Hospital | 2024-06-01 |
| A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (NCT06463834) | Fujian Cancer Hospital | 2024-03-20 |
| Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer (NCT06066216) | Fujian Cancer Hospital | 2024-02-01 |
| The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer (NCT06242392) | Fujian Cancer Hospital | 2024-01-31 |
| Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma (NCT06061445) | Fujian Cancer Hospital | 2024-01-09 |
| Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer (NCT06149767) | Fujian Cancer Hospital | 2024-01-01 |
| Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC (NCT06095167) | Fujian Cancer Hospital | 2024-01-01 |
| Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer (NCT06197438) | Fujian Cancer Hospital | 2024-01-01 |
| MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer (NCT06126393) | Fujian Cancer Hospital | 2024-01-01 |
| MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy (NCT06197126) | Fujian Cancer Hospital | 2024-01-01 |
| Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin (NCT05910177) | Fujian Cancer Hospital | 2023-12-28 |
| A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy (NCT06101966) | Fujian Cancer Hospital | 2023-12-01 |
| Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life (NCT06136962) | Fujian Cancer Hospital | 2023-12-01 |
| Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer (NCT05839470) | Fujian Cancer Hospital | 2023-11-19 |
| A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer (NCT06039982) | Fujian Cancer Hospital | 2023-11-01 |
| Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer (NCT06455046) | Fujian Cancer Hospital | 2023-10-11 |
| PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors (NCT06078670) | Fujian Cancer Hospital | 2023-10-10 |
| Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer (NCT05479240) | Fujian Cancer Hospital | 2023-09-01 |
| Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors (NCT05922358) | Fujian Cancer Hospital | 2023-09-01 |
| Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. (NCT05624099) | Fujian Cancer Hospital | 2023-08-01 |
| A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses (NCT05897138) | Fujian Cancer Hospital | 2023-08-01 |
| Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. (NCT05753826) | Fujian Cancer Hospital | 2023-08-01 |
| Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer (NCT05751265) | Fujian Cancer Hospital | 2023-07-01 |
| Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer (NCT05882630) | Fujian Cancer Hospital | 2023-06-01 |
| XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma (NCT05927844) | Fujian Cancer Hospital | 2023-06-01 |
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer (NCT05699655) | Fujian Cancer Hospital | 2023-05-10 |
| Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer (NCT06136910) | Fujian Cancer Hospital | 2023-05-09 |
| The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy (NCT05640726) | Fujian Cancer Hospital | 2023-05-01 |
| Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer (NCT05799443) | Fujian Cancer Hospital | 2023-04-05 |
| A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). (NCT05953909) | Fujian Cancer Hospital | 2023-02-01 |
| Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma (NCT05664139) | Fujian Cancer Hospital | 2023-02-01 |
| Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer (NCT06455072) | Fujian Cancer Hospital | 2023-02-01 |
| HRQOL in Locally Advanced Thyroid Carcinoma (NCT05824312) | Fujian Cancer Hospital | 2023-02-01 |
| Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma (NCT05675033) | Fujian Cancer Hospital | 2023-01-10 |
| Almonertinib Plus Metronomic Oral Vinorelbine (NCT05663177) | Fujian Cancer Hospital | 2022-12-20 |
| TIL Cells for the Treatment of the Advanced Solid Tumors Patients (NCT05649618) | Fujian Cancer Hospital | 2022-12-05 |
| Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer (NCT05595889) | Fujian Cancer Hospital | 2022-12-01 |
| TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors (NCT05648994) | Fujian Cancer Hospital | 2022-12-01 |
| Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer (NCT05597527) | Fujian Cancer Hospital | 2022-11-01 |
| An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas (NCT05928962) | Fujian Cancer Hospital | 2022-10-27 |
| Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain (NCT05561023) | Fujian Cancer Hospital | 2022-10-01 |
| Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines (NCT05519956) | Fujian Cancer Hospital | 2022-09-16 |
| the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy (NCT05497076) | Fujian Cancer Hospital | 2022-09-01 |
| To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer (NCT05335460) | Fujian Cancer Hospital | 2022-05-01 |
| TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer (NCT05314101) | Fujian Cancer Hospital | 2022-04-01 |
| the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer (NCT05131243) | Fujian Cancer Hospital | 2021-12-01 |
| Effects of Mobile Medicine on Cancer Patients (NCT05049811) | Fujian Cancer Hospital | 2021-11-01 |
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer (NCT05223088) | Fujian Cancer Hospital | 2021-10-31 |
| Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study (NCT04764006) | Fujian Cancer Hospital | 2021-10-13 |
| Tislelizumab as Cross-line Treatment for Advanced NSCLC (NCT05192681) | Fujian Cancer Hospital | 2021-10-10 |
| Study of FMT Combined With Nivolumab in Gastric Cancer (NCT05001360) | Fujian Cancer Hospital | 2021-10-01 |
| Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer (NCT05019690) | Fujian Cancer Hospital | 2021-10-01 |